Rani Therapeutics 

$0.8509
116
-$0.04-4.39% Friday 20:00
-$0.03-3.6%Friday 23:40After hours

Statistics

Day High
0.8537
Day Low
0.8431
52W High
2.85
52W Low
0.416
Volume
22,781
Avg. Volume
-
Mkt Cap
95.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.34
-0.24
-0.14
-0.04
Expected EPS
-0.05
Actual EPS
N/A

Financials

-1,817.09%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.63MRevenue
-29.67MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RANI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Organogenesis
ORGO
Mkt Cap308.82M
Organogenesis offers regenerative medicines which compete with Rani's therapeutic approach in healing and regeneration.
Medtronic
MDT
Mkt Cap107.36B
Medtronic, with its extensive range of medical devices, competes in the broader healthcare solutions space, including drug delivery systems similar to Rani's.
Inspire Medical Systems
INSP
Mkt Cap1.48B
Inspire Medical Systems offers innovative healthcare solutions that can be seen as alternatives to drug therapies, indirectly competing with Rani's offerings.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals focuses on creating transformative medicines, potentially competing in the same therapeutic areas as Rani.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie operates in the pharmaceuticals sector, developing drugs that could compete with Rani's therapeutic products.
AMGEN
AMGN
Mkt Cap196.12B
Amgen, a biotech firm, develops a wide range of treatments that could compete with Rani's drug delivery technology.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical company with a broad product line that could compete with Rani's therapies.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk specializes in diabetes care but also ventures into biopharmaceuticals, making it a competitor in some therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on rare disease treatments, potentially competing in niche markets targeted by Rani.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, known for its innovative medicines, competes in developing therapies that could overlap with Rani's market.

About

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Show more...
CEO
Mr. Mir A. Imran
Employees
105
Country
United States
ISIN
US7530181004

Listings

0 Comments

Share your thoughts

FAQ

What is Rani Therapeutics stock price today?
The current price of RANI is $0.85 USD — it has decreased by -4.39% in the past 24 hours. Watch Rani Therapeutics stock price performance more closely on the chart.
What is Rani Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Rani Therapeutics stocks are traded under the ticker RANI.
Is Rani Therapeutics stock price growing?
RANI stock has risen by +22.08% compared to the previous week, the month change is a +15.61% rise, over the last year Rani Therapeutics has showed a +59.94% increase.
What is Rani Therapeutics market cap?
Today Rani Therapeutics has the market capitalization of 95.63M
When is the next Rani Therapeutics earnings date?
Rani Therapeutics is going to release the next earnings report on August 06, 2026.
What were Rani Therapeutics earnings last quarter?
RANI earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.05 USD resulting in a +11.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rani Therapeutics revenue for the last year?
Rani Therapeutics revenue for the last year amounts to 1.63M USD.
What is Rani Therapeutics net income for the last year?
RANI net income for the last year is -29.67M USD.
How many employees does Rani Therapeutics have?
As of July 26, 2026, the company has 105 employees.
In which sector is Rani Therapeutics located?
Rani Therapeutics operates in the Health & Wellness sector.
When did Rani Therapeutics complete a stock split?
Rani Therapeutics has not had any recent stock splits.
Where is Rani Therapeutics headquartered?
Rani Therapeutics is headquartered in San Jose, United States.